Has affinity for and binding capability to red blood cells; NH2-CD4-GBP130-COOH; AIDS and HIV


Ontology type: sgo:Patent     


Patent Info

DATE

2009-09-08T00:00

AUTHORS

PRENDERGAST KENNETH F

ABSTRACT

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells. In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide. The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus. The resulting fusion peptide being exemplified as NH2-CD4-GBP130-COOH1-371 201-774 Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "PRENDERGAST KENNETH F", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/331076a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052824432", 
          "https://doi.org/10.1038/331076a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/331078a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032802761", 
          "https://doi.org/10.1038/331078a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/331082a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017707466", 
          "https://doi.org/10.1038/331082a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/331084a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018448137", 
          "https://doi.org/10.1038/331084a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/373117a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025418642", 
          "https://doi.org/10.1038/373117a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/337525a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048319402", 
          "https://doi.org/10.1038/337525a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/312767a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028751316", 
          "https://doi.org/10.1038/312767a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/373123a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014949926", 
          "https://doi.org/10.1038/373123a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/312763a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021684259", 
          "https://doi.org/10.1038/312763a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/273113a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020254632", 
          "https://doi.org/10.1038/273113a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/348411a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023911798", 
          "https://doi.org/10.1038/348411a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-09-08T00:00", 
    "description": "

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.

\n

In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.

\n

The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.

\n

The resulting fusion peptide being exemplified as\n

  • NH2-CD4-GBP130-COOH
  • 1-371 201-774
\n

\n

Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

", "endDate": "2026-09-08", "id": "sg:patent.US-7585508-B1", "name": "Has affinity for and binding capability to red blood cells; NH2-CD4-GBP130-COOH; AIDS and HIV", "sameAs": [ "https://app.dimensions.ai/details/patent/US-7585508-B1" ], "sdDataset": "patents", "sdDatePublished": "2022-10-01T07:03", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/patent/patent_21.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-7585508-B1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-7585508-B1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-7585508-B1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-7585508-B1'


 

This table displays all metadata directly associated to this object as RDF triples.

68 TRIPLES      14 PREDICATES      26 URIs      9 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-7585508-B1 schema:about anzsrc-for:11
2 anzsrc-for:1108
3 schema:author N9efb25fd4c7e49ceb0f1381c8fdcdf70
4 schema:citation sg:pub.10.1038/273113a0
5 sg:pub.10.1038/312763a0
6 sg:pub.10.1038/312767a0
7 sg:pub.10.1038/331076a0
8 sg:pub.10.1038/331078a0
9 sg:pub.10.1038/331082a0
10 sg:pub.10.1038/331084a0
11 sg:pub.10.1038/337525a0
12 sg:pub.10.1038/348411a0
13 sg:pub.10.1038/373117a0
14 sg:pub.10.1038/373123a0
15 schema:datePublished 2009-09-08T00:00
16 schema:description <p num="p-0001">Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.</p> <p num="p-0002">In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the <i>plasmodium vivax </i>Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.</p> <p num="p-0003">The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.</p> <p num="p-0004">The resulting fusion peptide being exemplified as <ul><li id="ul0001-0001" num="0000">NH2-CD4-GBP130-COOH</li><li id="ul0001-0002" num="0000">1-371 201-774</li></ul> </p> <p num="p-0005">Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.</p>
17 schema:endDate 2026-09-08
18 schema:name Has affinity for and binding capability to red blood cells; NH2-CD4-GBP130-COOH; AIDS and HIV
19 schema:sameAs https://app.dimensions.ai/details/patent/US-7585508-B1
20 schema:sdDatePublished 2022-10-01T07:03
21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
22 schema:sdPublisher N8d630152bb664147a5214ce8c441cdff
23 sgo:license sg:explorer/license/
24 sgo:sdDataset patents
25 rdf:type sgo:Patent
26 N7076c400899649d48adb45ec8e750f2b schema:name PRENDERGAST KENNETH F
27 rdf:type schema:Person
28 N8d630152bb664147a5214ce8c441cdff schema:name Springer Nature - SN SciGraph project
29 rdf:type schema:Organization
30 N9efb25fd4c7e49ceb0f1381c8fdcdf70 rdf:first N7076c400899649d48adb45ec8e750f2b
31 rdf:rest rdf:nil
32 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
33 rdf:type schema:DefinedTerm
34 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
35 rdf:type schema:DefinedTerm
36 sg:pub.10.1038/273113a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020254632
37 https://doi.org/10.1038/273113a0
38 rdf:type schema:CreativeWork
39 sg:pub.10.1038/312763a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021684259
40 https://doi.org/10.1038/312763a0
41 rdf:type schema:CreativeWork
42 sg:pub.10.1038/312767a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028751316
43 https://doi.org/10.1038/312767a0
44 rdf:type schema:CreativeWork
45 sg:pub.10.1038/331076a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052824432
46 https://doi.org/10.1038/331076a0
47 rdf:type schema:CreativeWork
48 sg:pub.10.1038/331078a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032802761
49 https://doi.org/10.1038/331078a0
50 rdf:type schema:CreativeWork
51 sg:pub.10.1038/331082a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017707466
52 https://doi.org/10.1038/331082a0
53 rdf:type schema:CreativeWork
54 sg:pub.10.1038/331084a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018448137
55 https://doi.org/10.1038/331084a0
56 rdf:type schema:CreativeWork
57 sg:pub.10.1038/337525a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048319402
58 https://doi.org/10.1038/337525a0
59 rdf:type schema:CreativeWork
60 sg:pub.10.1038/348411a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023911798
61 https://doi.org/10.1038/348411a0
62 rdf:type schema:CreativeWork
63 sg:pub.10.1038/373117a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025418642
64 https://doi.org/10.1038/373117a0
65 rdf:type schema:CreativeWork
66 sg:pub.10.1038/373123a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014949926
67 https://doi.org/10.1038/373123a0
68 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...